Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: Prospective randomized multicentre study

Italian Journal of Gastroenterology and Hepatology

Volumn 30, Issue 5, 1998, Pages 517-523

  Ascione, A ^a,b,c,d,e,f   De Luca, M ^a   Canestrini, C ^a   Di Costanzo, G G ^a   Raimondo, G ^a   Longo, G ^a   Manns, M P ^a   Tillmann, H L ^a   Forte, G B ^a   Rocco, P ^a   Biceglia, O ^a   Faleo, D ^a   Vinelli, F ^a   Maria Cela, E ^a   Amitrano, L ^a   Addario, L ^a   Gigliottl, T ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Azienda Ospedaliera Autonoma   (Italy)

^e Civil Hospital   (Italy)

^f NONE   (Italy)

Author keywords

Chronic hepatitis; Chronic liver disease; Cirrhosis; Hepatitis C; Interferon alpha

Indexed keywords

ANTIVIRUS AGENT; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0031796038     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatits C. N Eng J Med 1989; 321:1506-10.
2. Davis GL, Baiart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Eng J Med 1989;321:1501-6.
3. Kakumu S, Aroa M, Yoshioka K, Hayashi H, Kusakebe A, Hirofuji H, et al. Recombinant human a-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol 1990;85:655-9.
4. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicentre randomised controlled trial from France. Hepatology 1991;13:393-7.
5. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991:101:497-502.
6. Cimino L, Nardone G, Citarella C, Pema E, Capuano G, Budillon G. Treatment of chronic hepatitis C with recombinant inter-feron alfa. Ital J Gastroenterol 1991;23:399-402.
7. Varagona G, Brown D, Kibbler H, Scheuer P, Ashrafzadeh P, Sherlock S, et al. Response, relapse and re-treatment rates and viraemia in chronic hepatitis C treated with α2-b Interferon: a phase III study. Eur J Gastroenterol Hepatol 1992;4:707-12.
8. Gómez-Rubio M, Poires JC, Castillo J, Quiroga JA, Morena A, Carrefio V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alfa-interferon in comparison with a control group. J Hepatol 1990;11:563-7.
9. Reichard O, Foberg U, Frydén A, Mattsson L, Norkrans G, Sönnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-a2b for 60 weeks. Hepatology 1994;19:280-5.
10. Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas HC. Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J 1989;298:80-2.
11. Realdi G, Diodati G, Bonetti P, Scaccabarozzi S, Alberti A, Ruol A. Recombinant human interferon alfa-2a in community acquired non-A non-B chronic active hepatitis. Preliminary results of a randomized controlled trial. J Hepatol 1990; 11 :S68-71.
12. Ryff J-C. Usefulness of interferon for treatment of hepatitis C. J Hepatol 1995;22(Suppl.1):101-9.
13. Jacyna MR. Alfa-interferon therapy in chronic hepatitis C infection: what have we learnt so far? Eur J Gastroenterol Hepatol 1992;4:703-6.
14. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
15. Caporaso N, Suozzo R, Morisco F, D'Antonio M, Romano M, Cohort! M. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 1993;25:482-6.
16. Sàez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991;13:327-31.
17. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17:S123-6.
18. lino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of Chronic Hepatitis C with high-dose interferon a-2b: a multicenter study. Dig Dis Sei 1993;38:612-8.
19. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Baiart LA, Dienstag JL, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996;24:1034-40.
20. Jouet P, Roudot-Thoraval F, Dhumeaux D, Métreau JM and le Group Français pour l'étude du traitement des hepatites chroniques nanb/c. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106:686-90.
21. Lau JY, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 1993;342:1208-9.
22. Cammà C, Craxì A, Tiné F, Almasio P, Di Marco V, Lo lacono O, et al. Predictors of response to alpha-interferon (IFN) in chronic hepatitis C: a multivariate analysis on 361 treated patients. J Hepatol 1992;17:S1-20.
23. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995:332:1457-62.
24. Hagiwara H, Hayashi N, Mita E, Takahara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatits C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-83.
25. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamira K. A controlled study to determine the optimal dose regimen of interferon a 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-9.
26. Lin R, Roach E, Zimmerman M, Strasser S, Parrel G. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995;23:487-96.
27. Picciotto A, Callea F, Varagona G, Bardellini E, Borzone S, De Conca V, et al. Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver 1995;15:20-4.
28. Enn'quez J, Torras X, Miralles F, Martinez Cerezo FJ, Sancho Poch FJ, Buenestado J, et al. Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viremia and histological activity. J Viral Hepat 1995;2:181-7.
29. Marcellin P, Pouteau M, Martinot-Peignoux M, Degas F, Duchatelle V, Boyer N, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65.
30. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-a2a therapy in patients with chronic hepatitis C. Dig Dis Sei 1994;39:1273-80.
31. Saracco G, Rosina F, Torrani-Cerenzia MR, Lattore V, Chiandussi L, Gallo V, et al. A randomized controlled trial of interferon alpha 2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11 (Suppl l):S43-9.
32. Féray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992;89:1361-5.
33. Stuywer L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitic C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993:74:1093-102.
34. Armitage P, Berry G. Statistical methods in medical research. 2nd edn. Oxford: Blackwell, 1987.
35. Di Costanzo GO, Ascione A, Galeota Lanza A, De Luca M, Bracco A, Lojodice D, et ai. Resistance to alpha interferon therapy in HCV chronic liver disease: role of hepatic fibrosis. It J Gastroenterol 1996:28:140-6.
36. Chemello L, Albert! A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy.(Letter) N Engl J Med 1994:330:143.
37. Camps J, Garcia-Granero M, Riezu-Boj JI, Larrea E, de Alava E, Castilla MA, et al. Prediction of sustained remission of chronic hepatitis C after a course of alfa interferon. J Hepatol 1994:21:4-11.
38. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995:22:1326-9.
39. Garson JA, Brillanti S, Whitby K, Foli M, Deaville R, Masci C, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995:45:348-53.
40. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology 1996:24:778-89.
41. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997:336:347-56.
42. North Italian Endoscopie Club for study and treatment of esophageal varices. Prediction of the first variceal haemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicentre study. N Engl J Med 1988;319:983-92.
43. Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor E, et al. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial. J Hepatol 1997;27:52-6.
44. Testa R, Giannini E, Picciotto A, Risso D, Caglieris S, Fasoli A, et al. Probability of non-response during Interferon therapy in patients with chronic hepatitis C. Hepato-gastroenterol 1998 (in press).
45. Picciotto FP, Ascione A, Canestrini C, De Luca M, Galeota Lanza A, Guardascione MA, et al. Is the histological activity a predictive factor of response to interferon in HCV chronic liver disease? It J Gastroenterol 1996;28 (Suppl 2): 195.